Shandong Pharmaceutical Glass Co Ltd
SSE:600529
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (14.5), the stock would be worth ¥15.8 (17% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 17.5 | ¥19.11 |
0%
|
| 3-Year Average | 14.5 | ¥15.8 |
-17%
|
| 5-Year Average | 19.8 | ¥21.59 |
+13%
|
| Industry Average | 20.3 | ¥22.17 |
+16%
|
| Country Average | 20.8 | ¥22.7 |
+19%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
12.7B CNY | 17.5 | 18.4 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 36.2 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 17.4 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 16.5 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 20.9 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 15.2 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 36.2 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 20.8 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.7B CNY | 24.7 | 23.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -86.3 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Shandong Pharmaceutical Glass Co Ltd
Glance View
In the vast landscape of China's industrial might lies Shandong Pharmaceutical Glass Co Ltd., a company serving as a key player in the healthcare and pharmaceutical sectors. Established in 1970, the company has developed a reputation as a leading manufacturer and supplier of pharmaceutical packaging, particularly glass containers. It specializes in producing molded glass and glass tubing that form the backbone of safe and reliable drug delivery systems, including ampoules, vials, and cartridges. Over the decades, Shandong Pharmaceutical Glass Co Ltd. has leveraged its expertise in glass manufacturing to meet stringent industry standards and cater to the ever-evolving needs of its clients, ranging from pharmaceutical giants to smaller biotech firms. At the heart of its business model, Shandong Pharmaceutical Glass generates revenue by providing essential packaging solutions that are integral to the pharmaceutical supply chain. The company's success hinges on its ability to innovate and produce high-quality, durable glass products that ensure the integrity and safety of medicinal products during storage, transportation, and administration. With the rising global demand for pharmaceuticals, particularly in Asia Pacific markets, Shandong Pharmaceutical Glass's focus on sustainable, efficient, and technologically advanced manufacturing processes positions it strategically to capitalize on growth opportunities. By embedding itself in the pharmaceutical lifecycle, the company not only safeguards medications but also fortifies its own standing in a rapidly expanding industry.